The primary objective of this study is to prospectively examine outcomes in 12 patients using
ziconotide Intrathecal Drug Therapy(IDT) as first-line monotherapy with the use of an
algorithm of slow titration for dosing. The use of Prialt has demonstrated fewer and less
serious associated adverse effects as compared to IDT morphine, especially when titrated
slowly. We will use an average Numerical Rating Scale as our primary outcome and the Oswestry
Disability Index(ODI), Beck Depression Inventory (BDI), Pain Catastrophizing Scale (PCS),
Clinical Global Impression of Change Scale including binary satisfaction measures(CGIC),
Lawton-Brody Instrumental Activities of Daily Living(IADL) and Short Form-36 as secondary
outcome measures.